DZ3471A1 - Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2 - Google Patents
Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2Info
- Publication number
- DZ3471A1 DZ3471A1 DZ013471A DZ013471A DZ3471A1 DZ 3471 A1 DZ3471 A1 DZ 3471A1 DZ 013471 A DZ013471 A DZ 013471A DZ 013471 A DZ013471 A DZ 013471A DZ 3471 A1 DZ3471 A1 DZ 3471A1
- Authority
- DZ
- Algeria
- Prior art keywords
- bcl
- gene
- treating
- methods
- condition related
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22797000P | 2000-08-25 | 2000-08-25 | |
US23700900P | 2000-09-29 | 2000-09-29 | |
US09/709,170 US7795232B1 (en) | 2000-08-25 | 2000-11-10 | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
PCT/US2001/026414 WO2002017852A2 (fr) | 2000-08-25 | 2001-08-23 | Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2 |
Publications (1)
Publication Number | Publication Date |
---|---|
DZ3471A1 true DZ3471A1 (fr) | 2002-03-07 |
Family
ID=27397795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DZ013471A DZ3471A1 (fr) | 2000-08-25 | 2001-08-23 | Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2 |
Country Status (33)
Country | Link |
---|---|
US (2) | US7795232B1 (fr) |
EP (2) | EP2135623A1 (fr) |
JP (1) | JP2004507480A (fr) |
KR (1) | KR20030034153A (fr) |
CN (1) | CN1471408A (fr) |
AP (1) | AP2003002761A0 (fr) |
AT (1) | ATE432717T1 (fr) |
AU (2) | AU2001288373B2 (fr) |
BG (1) | BG107641A (fr) |
BR (1) | BR0113447A (fr) |
CA (1) | CA2419480A1 (fr) |
CY (1) | CY1109340T1 (fr) |
CZ (1) | CZ301582B6 (fr) |
DE (1) | DE60138892D1 (fr) |
DK (1) | DK1313514T3 (fr) |
DZ (1) | DZ3471A1 (fr) |
EA (1) | EA005424B1 (fr) |
EE (1) | EE200300074A (fr) |
ES (1) | ES2327904T3 (fr) |
GE (1) | GEP20063934B (fr) |
HK (1) | HK1056505A1 (fr) |
HR (1) | HRP20030102A2 (fr) |
HU (1) | HUP0303125A2 (fr) |
IL (1) | IL154409A0 (fr) |
MX (1) | MXPA03001575A (fr) |
NO (1) | NO20030858L (fr) |
OA (1) | OA12586A (fr) |
PL (1) | PL363050A1 (fr) |
PT (1) | PT1313514E (fr) |
SK (1) | SK3652003A3 (fr) |
UA (1) | UA77945C2 (fr) |
WO (1) | WO2002017852A2 (fr) |
YU (1) | YU13603A (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US7309692B1 (en) | 1996-07-08 | 2007-12-18 | Board Of Regents, The University Of Texas System | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1 |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
WO2003078662A1 (fr) | 2002-03-13 | 2003-09-25 | Genomic Health | Profilage d'expression genique dans des tissus tumoraux ponctionnes |
CA2505680A1 (fr) | 2002-11-14 | 2004-06-03 | Genta Salus Llc | Oliogonucleotides inhibiteurs diriges sur bcl-2 |
AU2003295598B2 (en) | 2002-11-15 | 2009-12-24 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
DE10258677A1 (de) * | 2002-12-13 | 2004-06-24 | Elez, Vera, Dr. | Kombinations-antisense-Oligonukleotid-Krebstherapie |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
ATE412779T1 (de) | 2003-02-20 | 2008-11-15 | Genomic Health Inc | Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression |
US20080020990A1 (en) | 2003-05-30 | 2008-01-24 | Nippon Shinyaku Co., Ltd. | Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same |
ES2787475T3 (es) | 2003-06-24 | 2020-10-16 | Genomic Health Inc | Predicción de probabilidad de recurrencia del cáncer |
ES2905579T3 (es) | 2003-07-10 | 2022-04-11 | Genomic Health Inc | Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama |
US20050196782A1 (en) | 2003-12-23 | 2005-09-08 | Kiefer Michael C. | Universal amplification of fragmented RNA |
GB0406415D0 (en) * | 2004-03-22 | 2004-04-21 | Inst Of Cancer Res The | Materials and methods for treatment of cancer |
EP2947160B1 (fr) | 2004-04-09 | 2017-07-12 | Genomic Health, Inc. | Marqueurs d'expression de genes permettant de predire une reponse a la chimiotherapie |
US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US8691963B2 (en) | 2004-08-26 | 2014-04-08 | Engeneic Molecular Delivery Pty. Ltd. | Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells |
AU2013203202B2 (en) * | 2004-08-26 | 2017-02-16 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived intact minicells |
AU2005304824B2 (en) | 2004-11-05 | 2011-12-22 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
ATE550440T1 (de) | 2004-11-05 | 2012-04-15 | Genomic Health Inc | Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung |
WO2007064857A2 (fr) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Formulation de liposomes amphoteres |
TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制bcl蛋白和結合夥伴間之交互作用的化合物及方法 |
CN100368424C (zh) * | 2006-07-21 | 2008-02-13 | 福建金山生物制药股份有限公司 | 抑制肿瘤的反义核苷酸 |
US20080171718A1 (en) * | 2006-11-08 | 2008-07-17 | Brown Bob D | Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents |
DE102007020554A1 (de) * | 2007-04-27 | 2008-10-30 | Henkel Ag & Co. Kgaa | Nukleinsäurehaltige kosmetische und/oder pharmazeutische Zubereitungen zur Behandlung epithelialen Deckgewebes |
US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
WO2009071681A2 (fr) * | 2007-12-07 | 2009-06-11 | Santaris Pharma A/S | Composés d'antagoniste d'arn utiles pour moduler bcl-2 |
AU2009316773A1 (en) * | 2008-11-21 | 2010-05-27 | Isis Pharmaceuticals, Inc. | Anticancer combination comprising docetaxel and an antisense oligonucleotide |
CN102712924A (zh) | 2009-07-30 | 2012-10-03 | 安提森斯制药有限公司 | 化疗药剂和TGF-β系统抑制剂的组合 |
KR101853509B1 (ko) * | 2010-01-06 | 2018-04-30 | 큐알엔에이, 인크. | 췌장 발달 유전자에 대한 천연 안티센스 전사체의 억제에 의한 췌장 발달 유전자와 관련된 질환의 치료 |
RS58823B1 (sr) | 2015-07-07 | 2019-07-31 | Hoffmann La Roche | Kombinovana terapija konjugatom anti-her2 antitelo-lek i bcl-2 inhibitorom |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2021231486A1 (fr) * | 2020-05-13 | 2021-11-18 | Unity Biotechnology, Inc. | Traitement du cancer par l'induction de sénescence suivie d'un sénolytique |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5015568A (en) | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5098890A (en) | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5734033A (en) | 1988-12-22 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Antisense oligonucleotides inhibiting human bcl-2 gene expression |
WO1991004014A1 (fr) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Procede de transport de compositions a travers la barriere hemato-encephalique |
WO1993020200A1 (fr) | 1992-04-02 | 1993-10-14 | Imperial Cancer Research Technology Limited | Cellules modifiees et procede de traitement |
WO1994008625A1 (fr) | 1992-10-21 | 1994-04-28 | Temple University - Of The Commonwealth System Of Higher Education | Combinaison d'un agent anti-neoplasique et d'oligonucleotides non codants dans le traitement du cancer |
US5550019A (en) | 1993-05-26 | 1996-08-27 | La Jolla Cancer Research Foundation | Methods of identifying compounds which alter apoptosis |
US5783683A (en) * | 1995-01-10 | 1998-07-21 | Genta Inc. | Antisense oligonucleotides which reduce expression of the FGFRI gene |
US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
-
2000
- 2000-11-10 US US09/709,170 patent/US7795232B1/en not_active Expired - Fee Related
-
2001
- 2001-08-23 UA UA2003032532A patent/UA77945C2/uk unknown
- 2001-08-23 CA CA002419480A patent/CA2419480A1/fr not_active Abandoned
- 2001-08-23 YU YU13603A patent/YU13603A/sh unknown
- 2001-08-23 AU AU2001288373A patent/AU2001288373B2/en not_active Ceased
- 2001-08-23 OA OA1200300058A patent/OA12586A/en unknown
- 2001-08-23 AU AU8837301A patent/AU8837301A/xx active Pending
- 2001-08-23 BR BR0113447-7A patent/BR0113447A/pt not_active IP Right Cessation
- 2001-08-23 AP APAP/P/2003/002761A patent/AP2003002761A0/en unknown
- 2001-08-23 SK SK365-2003A patent/SK3652003A3/sk unknown
- 2001-08-23 WO PCT/US2001/026414 patent/WO2002017852A2/fr active IP Right Grant
- 2001-08-23 JP JP2002522827A patent/JP2004507480A/ja not_active Withdrawn
- 2001-08-23 DK DK01968097T patent/DK1313514T3/da active
- 2001-08-23 ES ES01968097T patent/ES2327904T3/es not_active Expired - Lifetime
- 2001-08-23 MX MXPA03001575A patent/MXPA03001575A/es active IP Right Grant
- 2001-08-23 IL IL15440901A patent/IL154409A0/xx unknown
- 2001-08-23 CN CNA018177107A patent/CN1471408A/zh active Pending
- 2001-08-23 CZ CZ20030848A patent/CZ301582B6/cs not_active IP Right Cessation
- 2001-08-23 EP EP09007273A patent/EP2135623A1/fr not_active Withdrawn
- 2001-08-23 EA EA200300294A patent/EA005424B1/ru not_active IP Right Cessation
- 2001-08-23 EE EEP200300074A patent/EE200300074A/xx unknown
- 2001-08-23 PT PT01968097T patent/PT1313514E/pt unknown
- 2001-08-23 DZ DZ013471A patent/DZ3471A1/fr active
- 2001-08-23 DE DE60138892T patent/DE60138892D1/de not_active Expired - Lifetime
- 2001-08-23 HU HU0303125A patent/HUP0303125A2/hu unknown
- 2001-08-23 KR KR10-2003-7002605A patent/KR20030034153A/ko active Search and Examination
- 2001-08-23 PL PL01363050A patent/PL363050A1/xx not_active IP Right Cessation
- 2001-08-23 GE GE5129A patent/GEP20063934B/en unknown
- 2001-08-23 AT AT01968097T patent/ATE432717T1/de active
- 2001-08-23 EP EP01968097A patent/EP1313514B1/fr not_active Expired - Lifetime
-
2003
- 2003-02-13 HR HR20030102A patent/HRP20030102A2/hr not_active Application Discontinuation
- 2003-02-24 NO NO20030858A patent/NO20030858L/no unknown
- 2003-03-18 BG BG107641A patent/BG107641A/bg unknown
- 2003-11-28 HK HK03108693.0A patent/HK1056505A1/xx not_active IP Right Cessation
-
2009
- 2009-09-02 CY CY20091100919T patent/CY1109340T1/el unknown
-
2010
- 2010-04-02 US US12/753,285 patent/US20100216867A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DZ3471A1 (fr) | Methodes de traitement d'une pathologie en rapport avec le gene bcl-2 au moyen d'oligomeres antisens de bcl-2 | |
HUP0301805A3 (en) | Antisense oligonucleotides against vanilloid receptor 1 | |
ATE485394T1 (de) | Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai | |
NO20025724L (no) | Selvgående overflatebehandlende anordning | |
GB2367406B (en) | Predicated execution of instructions in processors | |
DE60111879D1 (de) | Inline-Pumpe | |
BR0106411B1 (pt) | processo de tratamento do lìquido residual de cromatização. | |
MXPA03005706A (es) | Barra limpiadora de la piel con altos niveles de emoliente liquido. | |
CY2010007I2 (el) | Προσδιορισμος in vivo δια την δοκιμασιαν της φαινοτυπικης σταθepοτητος | |
IL148155A0 (en) | Large circular target-specific antisense nucleic acid compounds | |
ATE254166T1 (de) | Konzentriertes flüssiges reinigungsmittel | |
BR0115699B1 (pt) | fluxÍmetro de massa giroscàpico e mÉtodo para operar o mesmo. | |
MA23595A1 (fr) | Oligonucleotides antisense | |
EP1437408A4 (fr) | Nouveaux derives oligonucleotidiques antisens contre le virus de l'hepatite c | |
DE19982513T1 (de) | Durchfluß-Chargenflüssigkeitsreiniger | |
AU5347101A (en) | Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof | |
FR2794621B1 (fr) | Procede de deformation permanente des cheveux au moyen d'un materiau filiforme | |
FR2814753B1 (fr) | Utilisations du gene gjb6 dans le traitement de certaines alopecies dont le syndrome de clouston, et pour le criblage de composes susceptibles d'etre efficaces dans le traitement d'alopecies avec predisposition genetique | |
RU93054766A (ru) | Олигорибонуклеотиды и их рибозимные аналоги с концевыми 3'-3'-соответственно, 5'-5'-связями | |
FI114616B (fi) | Keinuhevonen tai vastaava keinulaite | |
Quinn | Bottled Water Not Always As Clean As Advertised | |
FR2832420B1 (fr) | Sequence d'adn associee au syndrome d'alstrom(alms1) | |
ITRM20000077A0 (it) | Metodo per aumentare l'espressione genica per geni trasfettati. | |
NO20022799L (no) | Antisens oligonukleotider | |
ITPE20000003A1 (it) | Bici integrata 2000. |